Drug Trial Radar · NCT06109831
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic
Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
335
Actual
Start
Nov 24, 2023
Primary completion
Jul 4, 2025
Study completion Jul 4, 2025
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Stud to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with Hyperlipidemic.
Conditions
- Hyperlipidemic
Interventions
SHR-1918Drug
SHR-1918
SHR-1918 placeboDrug
SHR-1918 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in calculated LDL-C from baseline to week 16Time frame: from baseline to week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.